全文获取类型
收费全文 | 2538篇 |
免费 | 189篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 101篇 |
妇产科学 | 45篇 |
基础医学 | 493篇 |
口腔科学 | 41篇 |
临床医学 | 241篇 |
内科学 | 392篇 |
皮肤病学 | 112篇 |
神经病学 | 271篇 |
特种医学 | 83篇 |
外科学 | 176篇 |
综合类 | 13篇 |
预防医学 | 221篇 |
眼科学 | 55篇 |
药学 | 242篇 |
中国医学 | 7篇 |
肿瘤学 | 236篇 |
出版年
2024年 | 1篇 |
2023年 | 29篇 |
2022年 | 95篇 |
2021年 | 137篇 |
2020年 | 83篇 |
2019年 | 95篇 |
2018年 | 114篇 |
2017年 | 86篇 |
2016年 | 85篇 |
2015年 | 95篇 |
2014年 | 104篇 |
2013年 | 148篇 |
2012年 | 222篇 |
2011年 | 217篇 |
2010年 | 138篇 |
2009年 | 101篇 |
2008年 | 168篇 |
2007年 | 181篇 |
2006年 | 128篇 |
2005年 | 142篇 |
2004年 | 90篇 |
2003年 | 87篇 |
2002年 | 84篇 |
2001年 | 12篇 |
2000年 | 14篇 |
1999年 | 10篇 |
1998年 | 12篇 |
1997年 | 12篇 |
1996年 | 5篇 |
1995年 | 10篇 |
1994年 | 2篇 |
1993年 | 6篇 |
1992年 | 1篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1988年 | 3篇 |
1987年 | 2篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1982年 | 3篇 |
1980年 | 2篇 |
1978年 | 3篇 |
1977年 | 1篇 |
1973年 | 1篇 |
1970年 | 1篇 |
1969年 | 1篇 |
排序方式: 共有2742条查询结果,搜索用时 15 毫秒
101.
102.
Deep brain stimulation of the subthalamic nucleus (STN DBS) has become an accepted tool for the treatment of Parkinson's disease (PD). Although the precise mechanism of action of this intervention is unknown, its effectiveness has been attributed to the modulation of pathological network activity. We examined this notion using positron emission tomography (PET) to quantify stimulation-induced changes in the expression of a PD-related covariance pattern (PDRP) of regional metabolism. These metabolic changes were also compared with those observed in a similar cohort of patients undergoing STN lesioning. We found that PDRP activity declined significantly (P < 0.02) with STN stimulation. The degree of network modulation with DBS did not differ from that measured following lesioning (P = 0.58). Statistical parametric mapping (SPM) revealed that metabolic reductions in the internal globus pallidus (GPi) and caudal midbrain were common to both STN interventions (P < 0.01), although declines in GPi were more pronounced with lesion. By contrast, elevations in posterior parietal metabolism were common to the two procedures, albeit more pronounced with stimulation. These findings indicate that suppression of abnormal network activity is a feature of both STN stimulation and lesioning. Nonetheless, these two interventions may differ metabolically at a regional level. 相似文献
103.
104.
Trost M Carbon M Edwards C Ma Y Raymond D Mentis MJ Moeller JR Bressman SB Eidelberg D 《Annals of neurology》2002,52(6):853-856
The DYT1 dystonia mutation is associated with an abnormal metabolic brain network characterized by hypermetabolism of the basal ganglia, supplementary motor area, and the cerebellum. In this study, we quantified the activity of this network in carriers of other dystonia mutations to determine whether this functional abnormality is linked to genotype. The findings suggest that the DYT1 metabolic topography is not genotype specific and may be present in carriers of other dystonia mutations. 相似文献
105.
Tina Heiland Ulrike Zeitschel Maja A. Puchades Peer-Hendrik Kuhn Stefan F. Lichtenthaler Jan G. Bjaalie Maike Hartlage-Rübsamen Steffen Roßner Corinna Höfling 《Glia》2019,67(2):393-403
Transgenic Tg2576 mice expressing human amyloid precursor protein (hAPP) with the Swedish mutation are among the most frequently used animal models to study the amyloid pathology related to Alzheimer's disease (AD). The transgene expression in this model is considered to be neuron-specific. Using a novel hAPP-specific antibody in combination with cell type-specific markers for double immunofluorescent labelings and laser scanning microscopy, we here report that—in addition to neurons throughout the brain—astrocytes in the corpus callosum and to a lesser extent in neocortex express hAPP. This astrocytic hAPP expression is already detectable in young Tg2576 mice before the onset of amyloid pathology and still present in aged Tg2576 mice with robust amyloid pathology in neocortex, hippocampus, and corpus callosum. Surprisingly, hAPP immunoreactivity in cortex is restricted to resting astrocytes distant from amyloid plaques but absent from reactive astrocytes in close proximity to amyloid plaques. In contrast, neither microglial cells nor oligodendrocytes of young or aged Tg2576 mice display hAPP labeling. The astrocytic expression of hAPP is substantiated by the analyses of hAPP mRNA and protein expression in primary cultures derived from Tg2576 offspring. We conclude that astrocytes, in particular in corpus callosum, may contribute to amyloid pathology in Tg2576 mice and thus mimic this aspect of AD pathology. 相似文献
106.
Stepwise partitioning of Xp21: a profiling method for XK deletions causative of the McLeod syndrome 下载免费PDF全文
107.
Genetic Variants in the Vicinity of LGALS‐3 Gene and LGALS‐3 mRNA Expression in Advanced Carotid Atherosclerosis: An Exploratory Study 下载免费PDF全文
108.
Vladimir Stevanovic Irena Tabain Tatjana Vilibic-Cavlek Maja Mauric Maljkovic Iva Benvin Zeljka Hruskar Snjezana Kovac Iva Smit Gorana Miletic Suzana Hadina Vilim Staresina Lada Radin Valentina Plichta Branimir Skrlin Zoran Vrbanac Mirna Brkljacic Marija Cvetnic Josipa Habus Kresimir Martinkovic Iva Zecevic Gabrijela Jurkic Ivana Ferencak Zinka Stritof Matko Perharic Lovro Bucic Ljubo Barbic 《Viruses》2021,13(8)
Over a year into the COVID-19 pandemic, there is growing evidence that SARS-CoV-2 infections among dogs are more common than previously thought. In this study, the prevalence of SARS-CoV-2 antibodies was investigated in two dog populations. The first group was comprised of 1069 dogs admitted to the Veterinary Teaching Hospital for any given reason. The second group included dogs that shared households with confirmed COVID-19 cases in humans. This study group numbered 78 dogs. In COVID-19 infected households, 43.9% tested ELISA positive, and neutralising antibodies were detected in 25.64% of dogs. Those data are comparable with the secondary attack rate in the human population. With 14.69% of dogs in the general population testing ELISA positive, there was a surge of SARS-CoV-2 infections within the dog population amid the second wave of the pandemic. Noticeably seroprevalence of SARS-CoV-2 in the dog and the human population did not differ at the end of the study period. Male sex, breed and age were identified as significant risk factors. This study gives strong evidence that while acute dog infections are mostly asymptomatic, they can pose a significant risk to dog health. Due to the retrospective nature of this study, samples for viral isolation and PCR were unavailable. Still, seropositive dogs had a 1.97 times greater risk for developing central nervous symptoms. 相似文献
109.
The immune system has co-evolved with the infectious agents that challenge it, and in response pathogens have developed different mechanisms to subvert host immunity. A wealth of evidence suggests that infections are important components in the development of a functional immune system, and understanding the modulation of the host immune system by pathogens may offer new therapeutic strategies in a non-infectious setting. We investigated how infection with the protozoan parasite Trypanosoma brucei brucei (Tbb) modulates the autoimmune response to recombinant myelin oligodendrocyte glycoprotein (rMOG) in DBA/1 mice. Mice harbouring a Tbb infection did not develop experimental autoimmune encephalomyelitis (EAE) induced by immunization with rMOG in CFA, an animal model for the human autoimmune disease multiple sclerosis. Additionally, mice infected with the parasite at the time of immunization or 1 week later developed less severe EAE than uninfected controls. Protected mice displayed a markedly diminished rMOG-specific proliferation and IFNgamma production in lymph node cells and had correspondingly low titres of serum anti-rMOG IgG. Antigen-presenting cells (APCs) from spleens of Tbb-infected mice presented rMOG less efficiently to rMOG-specific T cells in vitro than did splenic APCs from uninfected mice and could also inhibit antigen-specific proliferation in control in vitro cultures. This suppressive effect is at least in part due to increased release of IL-10. Transfer of splenic APCs from Tbb-infected mice into mice immunized with rMOG-CFA 7 days previously abrogated disease significantly. These findings indicate that infections can prevent autoimmunity and that APCs might be used as immunomodulants. 相似文献
110.
Maja Jahnmatz Margaretha Ljungman Eva Netterlid Maria C. Jenmalm Lennart Nilsson Rigmor Thorstensson 《Clinical and Vaccine Immunology : CVI》2014,21(9):1301-1308
In order to impede the increase in pertussis incidence in the adolescent group, a school-leaving booster dose administered at the age of 14 to 16 years will be introduced in Sweden in 2016. Preceding this introduction, an open-label, randomized, multicenter, clinical trial without a control group and with blinded analysis was performed, investigating both safety and immunogenicity. Reported here are the memory B-cell and serological responses detected in a smaller cohort (n = 34) of the 230 subjects recruited to the study. All subjects had received primary vaccination consisting of three doses of diphtheria–tetanus–5-component pertussis (DTaP5) vaccine, at 3, 5, and 12 months of age, and a tetanus–low-dose diphtheria–5-component pertussis (Tdap5) vaccine booster at 5.5 years. In this study, the subjects were randomly assigned and received either a Tdap1 or Tdap5 booster. Of the 230 participants, 34 subjects had samples available for evaluation of IgG-producing memory B-cell responses. Both vaccine groups had significant increases in pertussis toxin-specific serum IgG levels, but only the 1-component group showed significant increases in pertussis toxin-specific memory B cells. The 5-component group had significant increases in filamentous hemagglutinin- and pertactin-specific memory B-cell and serum IgG levels; these were not seen in the 1-component group, as expected. In conclusion, this study shows that a 5th consecutive dose of an acellular pertussis vaccine induces B-cell responses in vaccinated adolescents. (This study has been registered at EudraCT under registration no. 2008-008195-13 and at ClinicalTrials.gov under registration no. NCT00870350.) 相似文献